Novartis’ LUTATHERA (lutetium Lu 177 dotatate) has already changed how gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are treated. Its approval for pediatric patients adds to this achievement and highlights Novartis’ role in advancing cancer care. While the lutathera cost continues to be debated, expanding access underlines the therapy’s value for younger patients...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
Bangla